immune checkpoint inhibitors, immune-related adverse events, immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Objective To observe the toxicities of immune checkpoint inhibitors. Methods We retrospectively analyzed the clinical data of 20 advanced tumor patients who received immune checkpoint inhibitors therapy in Cancer Hospital of Chinese Academy of Medical Sciences from March 2017 to August 2019, and collected the immune-related adverse events. Results The median immunotherapy time was 4.0 months. The immune-related adverse events occurred in 6 patients: one case of grade Ⅰ gastroenteritis, one case of grade Ⅰ dermatitis, one case of grade Ⅰ thyroiditis, one case of grade Ⅲ hepatitis, one case of grade Ⅲ pneumonia and one case of grade Ⅳ pneumonia; the median time of occurrence was 5.3 months. Conclusion As the incidence of immune-related adverse events is relatively high and sometimes life-threatening, it is crucial for early recognition, accurate diagnosis and prompt intervention of the toxicities associated with immune checkpoint inhibitors.